Clinical observation on the efficacy of mizolastine and ketotifen for treating chronic urticaria

Journal of Clinical Dermatology

Volumn 42, Issue 11, 2013, Pages 697-699

  Guo, Xiao Lan ^a   Yang, Wen Biao ^a   Huang, Fang Yi ^a   Ouyang, Zhi Bin ^a  

^a Stomatological Hospital of Jiangmen City   (China)

Author keywords

Chronic urticaria; Decremental therapy; Ketotifen; Mizolastine

Indexed keywords

KETOTIFEN; MIZOLASTINE;

ADVERSE OUTCOME; ARTICLE; CHRONIC URTICARIA; CLINICAL OBSERVATION; CONTROLLED STUDY; DROWSINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

EID: 84893142912     PISSN: 10004963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Roumestan C, Henriquet C, Gougat C, et al. Histamine H1-receptor antagonists inhibit nuclear factor-kappaB and activator protein-1 activities via H1-receptor-dependent and -independent mechanisms [J].Clin Exp Allergy, 2008, 38(6): 947-956. (Pubitemid 351725860)
2. Kaplan AP. What the first 10,000 patients with chronic urticaria have taught me:a personal journey [J]. J Allergy Clin Immunol, 2009, 123(3): 713-717.